Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000685

Drug Information
NameFlumazenil
SynonymsUPCMLD-DP137; Flumazenilo; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Mazicon; F 6300; EU-0100506; AC1Q33UE; CID3373; NCGC00025116-02; Romazicon; PDSP2_001761; Flumazenilum [Latin]; ZINC00001464; Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; NCGC00015439-07; 4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester; SBB063113; PDSP1_001778; Flumazenil [USAN:BAN:INN]; ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; nchembio747-comp37; CPD000058450; Ro15-1788; NCGC00025116-01; Flumazepil, Ro 15-1788, Anexate, Lanexat, Mazicon, Roma,Flumazenil; NCGC00025116-04; Ro 151788; SAM001246763; C15H14FN3O3; S1332_Selleck; Ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; AC1L1FSE; NCGC00015439-03; DB01205; BRN 4763661; MolPort-003-666-855; [3H]Ro15-1788; F6300_SIGMA; Flumazepil; Hoffman La Roche Brand of Flumazenil; Flumazenilum; MLS000028850; I01-0379; UPCMLD-DP137:001; NCGC00025116-05; HMS2089B15; MLS000759529; HMS2051D17; UNII-40P7XK9392; 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester; Lopac0_000506; 78755-81-4; Biomol-NT_000285; Ro 15-1788; Ro-15-1788; Lopac-F-6300; BIDD:GT0766; C07825; D005442; AC-6846; BRD-K98769987-001-01-3; CHEMBL407; LS-77778; Lanexat; Tocris-1328; RO-151788; CHEBI:5103; flumazenil; BPBio1_001190; Ro 15 1788; Roche Brand of Flumazenil; Romazicon (TN); NCGC00025116-03; MLS001076354; Flumazenil (JAN/USP/INN); Hoffman-La Roche Brand of Flumazenil; Ro-?15-1788; SMR000058450; NCGC00015439-01; TL8005362; D00697; Anexate
Trade NameAnexate; Lanexat; Mazicon; Romazicon
CompanyHoffmann-La Roche pharmaceutical company
IndicationGeneral anesthesia
[ICD9: 338   ICD10: R52]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(
10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
InChIKeyOFBIFZUFASYYRE-UHFFFAOYSA-N
Canonical SMILESCCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C    
Therapeutic ClassAntidotes
CAS NumberCAS 78755-81-4
FormulaC15H14FN3O3
PubChem Compound IDCID 3373.
PubChem Substance IDSID 10027.
ChEBI5103;
SuperDrug ATC IDV03AB25
SuperDrug CAS ID078755814;
TargetGamma-aminobutyric acid receptor subunit alpha-1Antagonist[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543